Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 2,406,104 shares, a decrease of 47.2% from the March 15th total of 4,553,371 shares. Based on an average daily trading volume, of 3,391,138 shares, the short-interest ratio is currently 0.7 days. Approximately 11.6% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Stock Performance

LGVN stock remained flat at $1.12 during mid-day trading on Tuesday. 790,582 shares of the company’s stock traded hands, compared to its average volume of 1,259,498. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.03. Longeveron has a 52-week low of $0.48 and a 52-week high of $1.83. The business has a fifty day simple moving average of $0.78 and a 200 day simple moving average of $0.71. The company has a market cap of $26.06 million, a price-to-earnings ratio of -0.87 and a beta of -0.18.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.20. The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.11 million. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%. On average, equities research analysts predict that Longeveron will post -3.69 EPS for the current fiscal year.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.